Regulatory approval
Published by the Health Canada.
Health Canada approved pertuzumab and trastuzumab in combination with chemotherapy for the adjuvant treatment of patients with HER2-poitive early breast cancer with lymph node positive and/hormone receptor negative disease.
This is written in the approval document as:
PHESGO (pertuzumab and trastuzumab) in combination with chemotherapy is indicated for the adjuvant treatment of patients with HER2-positive early breast cancer with lymph node positive and/or hormone receptor negative disease.
Citation
Therapeutic response
Precision oncology relationships for therapeutic response derived from this regulatory approval.
| Type | Biomarker(s) | Cancer type | Therapy(ies) |
|---|